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Abstract
Background: Clinically mild encephalitis/encephalopathy with a reversible splenial lesion (MERS) is a mild
encephalopathy caused by various pathological processes, but encephalopathy due to bacteria is rare.
Case presentation: We report the case of a 45-year-old Japanese woman who on receiving chemotherapy for
advanced breast cancer developed an altered mental status and dysarthria soon after fever from infection of a
subcutaneous implantable port. Staphylococcus aureus was detected in her blood cultures. Magnetic resonance
imaging (MRI) revealed an ovoid lesion in the central portion of the splenium of the corpus callosum (SCC).
Although hypotension was not observed, we diagnosed probable toxic shock syndrome (TSS) based on fever
(temperature: >38.9 °C), altered mental status, erythema, desquamation, thrombocytopenia, liver dysfunction,
and creatine phosphokinase elevation. We administered antimicrobial therapy and her neurological symptoms
improved gradually. The lesion in the SCC completely disappeared on MRI 7 days after disease onset.
Conclusions: We diagnosed this case as MERS caused by S. aureus bacteremia with TSS. This is the first report
of such a case, and we suggest that when a TSS patient presents with neurological symptoms, the possibility of
MERS should be considered.
Keywords: Clinically mild encephalitis/encephalopathy with a reversible splenial lesion, Toxic shock syndrome,
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Background
Mild encephalitis/encephalopathy with a reversible sple-
nial lesion (MERS) is a mild encephalopathy caused by
various pathological processes such as viral or bacterial
infections, drugs, metabolic and electrolyte abnormal-
ities, and trauma [1]. It is characterized by neurological
symptoms such as consciousness, vertigo, and seizure.
Several viruses (influenza virus, adenovirus, mumps
virus, varicella zoster virus [2, 3], rotavirus [4], measles
virus [5], and hepatitis A virus [6]) and bacteria (Escher-
ichia coli [7], Legionella pneumophila [8], and Myco-
plasma pneumoniae [9]) have been reported to cause
MERS, but bacteria are rarely the cause [2, 3]. Staphylo-
coccus aureus, especially, is a very rare cause of MERS,
and only one such case has been reported so far [10].
Moreover, there are no reports on MERS associated
with toxic shock syndrome (TSS).
We encountered a case of MERS caused by S. aureus
bacteremia with TSS and report our findings in this study.
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Case presentation
A 45-year-old Japanese woman had undergone chemo-
therapy for advanced breast cancer (TNM Classification
for Breast Cancer, T4N0M0; clinical Stage IIIb) for 2 years.
She had a subcutaneous implantable port attached to her
left subclavian vein and was receiving vinorelbine 11 days
before admission. A second dose of vinorelbine was ad-
ministered 4 days before admission. She developed fever
following pain and swelling at the site of the implantable
port 2 days before admission. She was suspected to have
catheter-related bloodstream infection and thus admitted
to our hospital. The implantable port was removed and pi-
peracillin/tazobactam was administered at 4.5 g every 8 h.
On hospital day 2, altered mental status and dysarthria
were observed.
At the onset of neurological symptoms, her vital signs
were as follows: blood pressure, 109/63 mmHg; pulse,
96 bpm; respiratory rate, 26 bpm; and temperature, 39.5 °C.
The Glasgow Coma Scale score for consciousness was 13
(eye opening, 4; verbal response, 4; and best motor re-
sponse, 5). No obvious paralysis was noted, although evalu-
ation of neurological symptoms was difficult because of
disorders of consciousness. Conjunctival hyperemia was
noted. Except for the subclavian lesion at the site of the im-
plantable port, no abnormalities of the skin, lung, heart,
and abdomen were noted. The subclavian lesion was red
and swollen. Laboratory test results were as follows: white
blood cell count 400/mm3; hemoglobin, 9.9 g/dl; plate-
let, 6.2 × 104/mm3; blood urea nitrogen, 15 mg/dl; cre-
atinine, 0.69 mg/dl; aspartate aminotransferase, 48 U/l;
alanine aminotransferase, 26 U/l; lactate dehydrogen-
ase, 353 U/l; creatine phosphokinase, 1859 U/l; serum
sodium, 130 mEq/l; serum potassium, 3.3 mEq/l; and
C-reactive protein, 13.5 mg/dl (Table 1). Head magnetic
resonance imaging (MRI) revealed an ovoid high-intensity
lesion in the central portion of the SCC on diffusion-
weighted imaging (DWI, Fig. 1). Based on the MRI findings,
septic embolus or cerebral infarction was considered be-
cause the neurological symptoms occurred suddenly follow-
ing fever due to catheter-related bloodstream infection. On
the same day, gram-positive cocci were detected in blood
cultures. Therefore, on hospital day 2, piperacillin/
Table 1 Laboratory data on hospital day 2
Parameter Recorded value Standard value
White blood cell count 0.40 × 109/L 4.00–7.50 × 109/L
Neutrophil 0.30 × 109/L
Monocyte 0.01 × 109/L
Lymphocyte 0.09 × 109/L
Hemoglobin 9.9 g/dL 11.3–15.2 g/dL
Hematocrit 35.8 % 36–45 %
Platelet 6.2 × 109/L 130–350 × 109/L
C-reactive protein 13.5 mg/dL ≤0.14 mg/dL
Total protein 6.1 g/dL 6.9–8.4 g/dL
Albumin 2.9 g/dL 3.9–5.1 g/dL
Aspartate aminotransferase 48 U/L 11–30 U/L
Alanine aminotransferase 26 U/L 4–30 U/L
Lactate dehydrogenase 353 U/L 109–216 U/L
Creatine phosphokinase 1859 U/L 40–150 U/L
Blood nitrogen urea 15 mg/dL 8–20 mg/dL
Creatinine 0.69 mg/dL 0.63–1.03 mg/dL
Sodium 138 mEq/L 136–148 mEq/L
Potassium 4.2 mEq/L 3.6–5.0 mEq/L
Glucose 124 mg/dl 70–109 mg/dl
Fig. 1 Head magnetic resonance imaging on admission day 2. a Diffusion-weighted imaging (DWI), b Apparent diffusion coefficient (ADC). Head
magnetic resonance imaging revealed an ovoid lesion in the central portion of the splenium of the corpus callosum. The lesion appears as
reduced diffusion on DWI and has a low ADC value (red circles)
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tazobactam therapy was switched to cefepime and vanco-
mycin. On hospital day 4, methicillin-sensitive S. aureus
(MSSA) was detected in blood cultures. Nafcillin and oxa-
cillin, the first treatment of choice for MSSA-related dis-
eases of the central nervous system, are not available in
Japan. Therefore, cefepime was administered at 2 g every
8 h.
The patient's altered mental status and dysarthria im-
proved gradually. On hospital day 9, 7 days after disease
onset, the ovoid lesion had completely disappeared on
MRI (Fig. 2).
Conjunctival congestion and erythema developed on hos-
pital days 2 and 3, respectively. Aspartate aminotransferase,
alanine aminotransferase, and creatine phosphokinase
levels were high at 137, 88, and 11,240 U/l on hospital
days 8, 4, and 8, respectively. Soon erythema developed,
and desquamation occurred 2 weeks after disease onset.
In addition, isolated MSSA strains produced toxic shock
syndrome toxin-1 (TSST-1). Although hypotension was not
seen, probable TSS was diagnosed from fever (temperature,
>38.9 °C), erythema, desquamation, creatine phosphokinase
elevation, liver dysfunction, thrombocytopenia, and altered
mental status [11, 12].
On hospital day 12, we switched from cefepime to
vancomycin plus ceftriaxone because of drug eruption.
On hospital day 15, we switched from vancomycin plus
ceftriaxone to cefazolin at 2 g every 8 h, because due to
the following reasons we concluded it was not neces-
sary to consider cerebrospinal fluid (CSF) penetration
by the antimicrobial agent: (i) CSF examination results
Fig. 2 Head magnetic resonance imaging (MRI). a Diffusion-weighted imaging on admission day 2, b Diffusion-weighted imaging on admission
day 9. Abnormalities detected on MRI completely disappeared on admission day 9 (red circles)
Fig. 3 Patient's clinical course after hospitalization. Abbreviations: MSSA, methicillin-sensitive Staphylococcus aureus; magnetic resonance
imaging, MRI
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were unremarkable and culture negative, (ii) abnormal
findings on head MRI were due to MERS, and (iii) mul-
tiple organ injuries were due to TSS.
Figure 3 shows the clinical course post admission.
Transesophageal echocardiography revealed no abnor-
malities. Moreover, septic emboli were not detected by
enhanced computed tomography of the neck, chest,
abdomen, and pelvis. We continued antibiotic therapy
for 4 weeks after the blood cultures tested negative, i.e.,
after hospital day 4. At the 6-month follow up, no
recurrence was noted.
Discussion
We describe a rare case of MERS caused by S. aureus
bacteremia with probable TSS. MERS is caused by vari-
ous viruses, such as influenza, mumps, adenovirus, vari-
cella, and zoster virus, but rarely by bacteria [7, 9]. Thus
far, only one case of MERS caused by S. aureus has been
reported [10]. To the best of our knowledge, this is the
first reported case of MERS with TSS.
MRI is useful for diagnosing MERS [1, 13] as MRI scans
can reveal lesions in the SCC. In a case reported by Doherty
et al., the lesion presented as reduced diffusion on DWI,
had a low ADC value, and disappeared within a month.
The radiological findings of our case were typical of MERS
[1]. Acute disseminated encephalomyelitis (ADEM) is sug-
gested to be considered as a differential diagnosis of post-
infection encephalopathy [13]. In our case, the splenial
lesion completely disappeared a week before clinical re-
covery, thus ruling out ADEM. Other differential diagno-
ses include ischemia, posterior reversible encephalopathy
syndrome, diffuse axonal injury, multiple sclerosis,
hydrocephalus, Marchiafava-Bignami disease, lymph-
oma, and extrapontine myelinolysis [13]. All were
excluded clinically.
Our patient had a catheter-related bloodstream infec-
tion caused by MSSA. Probable TSS was diagnosed as the
case met all the diagnostic criteria except hypotension and
gastrointestinal symptoms [12] (Table 2). TSS is character-
ized by multiple organ impairment due to S. aureus exo-
toxin [11]. Staphylococcal exotoxins can activate several T
cells at once, resulting in massive cytokine production
[14]. Activated T cells release interleukin (IL)-1, IL-2,
tumor necrosis factor (TNF)-alpha, TNF-beta, and
interferon-gamma in large amounts, resulting in TSS
[15]. Although the mechanism of MERS is unknown,
Tada et al. postulated two possible mechanisms for the
transiently decreased ADC value of the lesions, intra-
myelinic edema, and inflammatory infiltrate [2]. We sup-
pose that the inflammatory infiltrate caused by cytokine
cascades of TSS are involved in the pathogenesis of MERS
in our case.
Although MERS coexisting with TSS is extremely
rare, staphylococcal exotoxins may cause MERS. Since
our patient did not have hypotension, we could perform
head MRI. Typically, TSS presents with hypotension
and poor general conditions, hindering MRI. Thus, one
cannot ignore MERS coexisting with TSS.
Table 2 Diagnostic categories of toxic shock syndrome (TSS)
Definite TSS (all criteria must be present) [11]
Clinical Criteria
An illness with the following clinical manifestations:
• Fever: temperature greater than or equal to 102.0 °F (greater than or
equal to 38.9 °C)
• Rash: diffuse macular erythroderma
• Desquamation: 1–2weeks after onset of rash
• Hypotension: systolic blood pressure less than or equal to 90 mmHg
for adults or less than the fifth percentile by age for children aged
less than 16 years
• Multisystem involvement (three or more of the following organ
systems):
º Gastrointestinal: vomiting or diarrhea at onset of illness
º Muscular: severe myalgia or creatine phosphokinase level at least
twice the upper limit of normal
º Mucous membrane: vaginal, oropharyngeal, or conjunctival
hyperemia
º Renal: blood urea nitrogen or creatinine at least twice the upper
limit of normal for laboratory or urinary sediment with pyuria
(greater than or equal to 5 leukocytes per high-power field) in
the absence of urinary tract infection
º Hepatic: total bilirubin, alanine aminotransferase enzyme, or
aspartate aminotransferase enzyme levels at least twice the upper
limit of normal for laboratory
º Hematologic: platelets less than 100,000/mm3
º Central nervous system: disorientation or alterations in
consciousness without focal neurologic signs when fever and
hypotension are absent
Laboratory Criteria for Diagnosis
Negative results on the following tests, if obtained:
• Blood or cerebrospinal fluid cultures (blood culture may be positive
for Staphylococcus aureus)
• Negative serologies for Rocky Mountain spotted fever, leptospirosis,
or measles
Probable TSS (≥3 criteria and desquamation or ≥5 criteria without
desquamation) [12]
• Temperature ≥38.9 °C
• Rash
• Hypotension, orthostatic dizziness, or syncope
• Myalgia
• Vomiting, diarrhea, or both
• Mucous membrane inflammation (conjunctivitis, pharyngitis,
vaginitis)
• Clinical or laboratory abnormalities of ≥2 organ systems
• Reasonable evidence for absence of other etiologies
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Conclusions
To conclude, we report the world's first case of MERS
caused by S. aureus bacteremia with TSS, and suggest that
when a patient with TSS presents neurological symptoms,
MERS should be considered.
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